2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Cisplatin
182
Radiotherapy
81
Paclitaxel
80
Brachytherapy
74
Carboplatin
72
pembrolizumab
63
Bevacizumab
40
Surveys and Questionnaires
29
Colposcopy
29
Radiation
28
Gemcitabine
28
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
27
Topotecan
26
Magnetic Resonance Spectroscopy
24
Blood Specimen Collection
23
human papillomavirus vaccine, L1 type 16, 18
22
Nivolumab
22
Drug Therapy
22
Papillomavirus Vaccines
20
atezolizumab
19
Platinum
19
Radiotherapy, Intensity-Modulated
18
Biopsy
18
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled